Detalhe da pesquisa
1.
Cardiovascular, bone, and metabolic health in men with castrate-resistant prostate cancer treated with androgen deprivation: a matched cohort study.
Acta Oncol
; 61(11): 1377-1385, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448630
2.
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
Am J Hematol
; 96(1): 23-30, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32936979
3.
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Eur J Haematol
; 103(6): 614-619, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31536656
4.
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Am J Hematol
; 96(3): E63-E65, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264449
5.
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Br J Haematol
; 164(5): 684-93, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24313224
6.
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Eur J Haematol
; 92(1): 19-25, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24118547
7.
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Acta Haematol
; 130(1): 7-15, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23363691
8.
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.
Cell Rep Med
; 3(2): 100508, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243416
9.
Involved free light chain: an early independent predictor of response and progression in multiple myeloma.
Leuk Lymphoma
; 62(9): 2227-2234, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33797301
10.
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.
Eur J Health Econ
; 22(1): 169-180, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33275188
11.
The Alignment of Real-World Evidence and Digital Health: Realising the Opportunity.
Ther Innov Regul Sci
; 55(4): 889-898, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914297
12.
Real world treatment utilization patterns in patients with castration-resistant prostate cancer.
Scand J Urol
; 55(4): 299-306, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096469
13.
Bridging the Gap Between RCTs and RWE Through Endpoint Selection.
Ther Innov Regul Sci
; 55(1): 90-96, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32632753
14.
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Eur J Haematol
; 85(6): 484-91, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20846301
15.
Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.
Scand J Urol
; 54(2): 115-121, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32266854
16.
Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data.
J Comp Eff Res
; 9(3): 155-159, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31964167
17.
Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer-A Systematic Literature Review and Pooling of Individual Participant Data.
Eur Urol Focus
; 5(5): 788-798, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29627197
18.
Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection.
Ther Innov Regul Sci
; 55(1): 97, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128171
19.
Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.
Clin Drug Investig
; 34(1): 43-52, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24178237
20.
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
PLoS One
; 9(7): e101819, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25003848